Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029597 | 0.92 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9ATGM2CA12 | |
| Hydrochloric Acid SCHEMBL9957962 | 0.90 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ATGM2CA12 | |
| Methylamine SCHEMBL11079802 | 0.88 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9ATGM2CA12 | |
| SCHEMBL27465968 | 0.85 | PTPN1 (0.69) | ALDH1A1NPC1RAB9AMITFMEN1 | |
| Nitric Acid SCHEMBL4613840 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TGM2CA12CA1CA2 | |
| Phenylguanidine SCHEMBL300643 | 0.81 | TP53 (0.56) | ALDH1A1NPC1RAB9ATGM2MEN1 | |
| Phenylguanidine SCHEMBL1950328 | 0.81 | TP53 (0.56) | ALDH1A1NPC1RAB9ATGM2MEN1 | |
| Bicarbonate SCHEMBL3281891 | 0.80 | NPC1 (0.64) | ALDH1A1NPC1RAB9ACA12CA1 | |
| SCHEMBL1996992 | 0.80 | F2 (0.50) | ALDH1A1NPC1RAB9AGAATP53 | |
| Bicarbonate SCHEMBL2945476 | 0.79 | KIF11 (0.62) | NPC1RAB9ATGM2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981917-B2 | Preparation method for revaprazan hydrochloride | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-05-29 | — | — | US | claimed |
| US-20170267646-A1 | PREPARATION METHOD FOR REVAPRAZAN HYDROCHLORIDE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2017-09-21 | — | — | US | claimed |
| CN-106986833-A | Auspicious pula life impurity and preparation method thereof | 广东华南药业集团有限公司 | 2017-07-28 | — | — | CN | claimed |
| EP-0900214-B1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORP (KR) | 2001-09-26 | — | — | EP | claimed |
| US-6252076-B1 | REACTING 4-FLUOROGUANIDINE CARBONATE WITH ETHYL 2-METHYLACETOACETATE | YUHAN CORPORATION (KR) | 2001-06-26 | — | — | US | claimed |
| EP-0900214-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | Yuhan Corporation (KR) | 1999-03-10 | — | — | EP | claimed |
| WO-1997042186-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 1997-11-13 | — | — | WO | claimed |
| CN-105669642-B | Preparation method of loflupridine hydrochloride | 江苏天士力帝益药业有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-9981917-B2 | Preparation method for revaprazan hydrochloride | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170267646-A1 | PREPARATION METHOD FOR REVAPRAZAN HYDROCHLORIDE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| CN-106986833-A | Auspicious pula life impurity and preparation method thereof | 广东华南药业集团有限公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-105669642-A | Revaprzan hydrochloride preparation method | 江苏天士力帝益药业有限公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-102993173-A | Preparation method of revaprzan hydrochloride | UNIV SHANDONG | 2013-03-27 | — | — | CN | disclosed |
| US-6252076-B1 | REACTING 4-FLUOROGUANIDINE CARBONATE WITH ETHYL 2-METHYLACETOACETATE | YUHAN CORPORATION (KR) | 2001-06-26 | — | — | US | disclosed |
| CN-1251586-A | Noval pyrimidine derivatives and process and preparing thereof | YUHAN CORP (KR) | 2000-04-26 | — | — | CN | disclosed |
| US-5990311-A | Process for preparation of pyrimidine derivatives | UHAN CORPORATION (KR) | 1999-11-23 | — | — | US | disclosed |
| CN-1217722-A | Process for preparing pyrimidine derivatives | YUHAN CORP (KR) | 1999-05-26 | — | — | CN | disclosed |
| EP-0900214-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | Yuhan Corporation (KR) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998018784-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 1998-05-07 | — | — | WO | disclosed |
| WO-1997042186-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267646-A1 | PREPARATION METHOD FOR REVAPRAZAN HYDROCHLORIDE | DPYD, QDPR, REV1 | ALDH1A1 504/4885NPC1 3824/4885RAB9A 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.